

## **Director/PDMR Shareholding**

May 25, 2016 11:00 AM ET

**25 May 2016**

## **Director/PDMR Shareholding**

LivaNova PLC (the “**Company**” or “**LivaNova**”) announces on 25 May 2016, that Daniel J. Moore, who is a PDMR and Director of LivaNova, on 23 May 2016 disposed of 300 ordinary shares of £1.00 each in the capital of the Company (the “**Ordinary Shares**”) for an average price of US \$50.0733 per Ordinary Share. In addition, on 24 May 2016, Daniel J. Moore disposed of 700 ordinary shares of £1.00 each in the capital of the Company (the “**Ordinary Shares**”) for an average price of US \$50.09 per Ordinary Share. The shares were sold pursuant to Mr. Moore’s plan adopted by him on 30 November 2015 under Rule 10b5-1 established by the U.S. Securities and Exchange Commission. As a result of this transaction, Daniel J. Moore currently holds 64,437 Ordinary Shares, representing 0.13 per cent of the Company’s issued share capital (which excludes the 2,233 Ordinary Shares that he is entitled to in relation to his Restricted Stock Units (subject to vesting periods and the terms of the LivaNova 2015 Incentive Award Plan)).

This announcement is made pursuant to the Disclosure and Transparency Rule 3.1.4R.

Further details and a copy of the applicable Form 4, “Statement of Changes in Beneficial Ownership of Securities,” to be filed with the U.S. Securities & Exchange Commission, can be found at the SEC website, [www.sec.gov](http://www.sec.gov), and the LivaNova PLC web site, [www.livanova.com](http://www.livanova.com)

## **About LivaNova**

LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.

For more information, please visit [www.livanova.com](http://www.livanova.com), or contact:

## **Investor Relations and Media**

### **Karen King**

Vice President, Investor Relations & Corporate Communications

Phone: +1 (281) 228-7262

Fax: +1 (281) 218-9332

e-mail: [corporate.communications@livanova.com](mailto:corporate.communications@livanova.com)